drugset / Trial / NCT00088530
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
RandomizedParallel-groupOpen-labelTreatment
Summary
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore).
Timeline
- Start
- 2004-07
- Primary completion
- 2010-02
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Etoposide | Small molecule | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Comparator | Ifosfamide | Small molecule | — | — |
| Comparator | Mitoxantrone | Small molecule | — | — |
| Comparator | Oxaliplatin | Small molecule | — | — |
| Subject | Pixantrone | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Comparator | Vinorelbine | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 100 mg | — |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | — |